JP2009535390A5 - - Google Patents

Download PDF

Info

Publication number
JP2009535390A5
JP2009535390A5 JP2009508465A JP2009508465A JP2009535390A5 JP 2009535390 A5 JP2009535390 A5 JP 2009535390A5 JP 2009508465 A JP2009508465 A JP 2009508465A JP 2009508465 A JP2009508465 A JP 2009508465A JP 2009535390 A5 JP2009535390 A5 JP 2009535390A5
Authority
JP
Japan
Prior art keywords
acid
thieno
pyrimidin
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009508465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535390A (ja
JP5329395B2 (ja
Filing date
Publication date
Priority claimed from GBGB0608820.7A external-priority patent/GB0608820D0/en
Application filed filed Critical
Publication of JP2009535390A publication Critical patent/JP2009535390A/ja
Publication of JP2009535390A5 publication Critical patent/JP2009535390A5/ja
Application granted granted Critical
Publication of JP5329395B2 publication Critical patent/JP5329395B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009508465A 2006-05-04 2007-05-04 医薬化合物 Expired - Fee Related JP5329395B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0608820.7A GB0608820D0 (en) 2006-05-04 2006-05-04 Pharmaceutical compounds
GB0608820.7 2006-05-04
PCT/GB2007/001644 WO2007132171A1 (en) 2006-05-04 2007-05-04 Pharmaceutical compounds

Publications (3)

Publication Number Publication Date
JP2009535390A JP2009535390A (ja) 2009-10-01
JP2009535390A5 true JP2009535390A5 (https=) 2010-06-24
JP5329395B2 JP5329395B2 (ja) 2013-10-30

Family

ID=36603916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009508465A Expired - Fee Related JP5329395B2 (ja) 2006-05-04 2007-05-04 医薬化合物

Country Status (8)

Country Link
US (1) US8153639B2 (https=)
EP (1) EP2035431B1 (https=)
JP (1) JP5329395B2 (https=)
CN (1) CN101479276B (https=)
CA (1) CA2651136C (https=)
ES (1) ES2562935T3 (https=)
GB (1) GB0608820D0 (https=)
WO (1) WO2007132171A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2470936C2 (ru) 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
MX2009005950A (es) 2006-12-07 2009-10-12 Genentech Inc Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
BRPI0813629A2 (pt) * 2007-07-26 2018-07-10 Novartis Ag derivados de pirimidina úteis no tratamento de condições inflamatórias ou alérgicas
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
CA2725014C (en) 2008-05-30 2014-06-17 Amgen Inc. Inhibitors of pi3 kinase
US8163743B2 (en) * 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
CA2729045A1 (en) 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
JP2012521354A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
CN102361878A (zh) 2009-03-24 2012-02-22 住友化学株式会社 用于制备硼酸酯化合物的方法
LT2899191T (lt) 2009-04-30 2017-10-25 Glaxo Group Limited Oksazolo pakeistieji indazolai kaip pi3-kinazės inhibitoriai
BRPI1009022A2 (pt) 2009-05-27 2016-03-08 Hoffmann La Roche "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
US8158625B2 (en) 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
CA2768843A1 (en) * 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
JP5579864B2 (ja) 2009-11-12 2014-08-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｎ−９−置換プリン化合物、組成物及び使用の方法
EP2499143B1 (en) 2009-11-12 2016-03-16 F.Hoffmann-La Roche Ag N7-substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
TW201500358A (zh) 2010-12-16 2015-01-01 赫夫門羅氏藥廠股份有限公司 三環ｐｉ３ｋ抑制劑化合物及其使用方法
US9499561B2 (en) 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
EP3053926B1 (en) 2013-09-30 2018-08-08 Shanghai Yingli Pharmaceutical Co. Ltd. Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
KR100774855B1 (ko) * 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
CN1894222A (zh) 2003-08-05 2007-01-10 沃泰克斯药物股份有限公司 作为电压门控离子通道抑制剂的稠合嘧啶化合物
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
JP2009535390A5 (https=)
CN114163457B (zh) 嘧啶并五元氮杂环化合物及其用途
JP7215687B2 (ja) キナーゼ阻害活性を有する化合物、その製造方法及び用途
AU2006249847B2 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
JP6511430B2 (ja) がんの治療のための化合物および組成物
RU2008145663A (ru) Производное тиено[3,2-d]пиримидина в качестве ингибитора фосфатидилинозитол-3-киназы (рi3к)
CN112390814B (zh) Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗
US10548883B2 (en) Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor
JP2011521968A5 (https=)
TW202521549A (zh) 一種稠環化合物及在ｋｒａｓ抑制劑方面的應用
CN102225926A (zh) 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
TWI800489B (zh) Ｆｇｆｒ４抑制劑及其製備方法和應用
JP6207625B2 (ja) チロシンキナーゼ阻害剤としてのインドリノン誘導体
WO2016208592A1 (ja) 二環性複素環アミド誘導体
CN115697987B (zh) 雌激素受体调节剂化合物及其用途
JP6239149B2 (ja) 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
TW201829396A (zh) 嘧啶化合物及包括其的藥學組成物
TW201321371A (zh) 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物
JP2021504457A (ja) チエノ環系化合物およびその合成方法と応用
US20060094728A1 (en) Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
CN108727361A (zh) 吲哚胺2,3-双加氧酶抑制剂与应用
CN113004285B (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
CN114341135B (zh) 雌激素相关受体α(ERRα)调节剂
JP6564394B2 (ja) 複素環式化合物およびそのドーパミンｄ１リガンドとしての使用
CN108299420B (zh) 作为选择性雌激素受体下调剂的五环类化合物及其应用